抗PD-L1单克隆抗体与EGFR-TKI对EGFR突变肺癌细胞PD-L1表达及T淋巴细胞功能的影响
该研究采用流式细胞术和ELISA检测EGFR突变及野生型肺癌细胞在厄洛替尼处理前后膜型PD-L1和可溶性PD-L1的表达,并在共培养体系中观察抗PD-L1单克隆抗体单用及联用厄洛替尼对T淋巴细胞增殖的影响。结果显示厄洛替尼可下调EGFR突变肺癌细胞PD-L1表达并促进T细胞增殖,联合抗PD-L1抗体作用更强。
要点
- 厄洛替尼下调EGFR突变PC9和HCC827细胞的膜型及可溶性PD-L1表达。
- 厄洛替尼单药促进共培养体系中T淋巴细胞增殖,联合抗PD-L1抗体作用更强。
- EGFR野生型H1299和A549细胞中厄洛替尼对PD-L1及T细胞功能无显著影响。
核心结论
- 抗PD-L1单克隆抗体联合EGFR-TKI可有效促进EGFR突变肺癌细胞微环境中T淋巴细胞的增殖和分泌功能。
研究设计与样本
- 实验研究,使用EGFR突变肺癌细胞PC9和HCC827及EGFR野生型肺癌细胞H1299和A549进行体外实验。
主要发现
- PC9细胞膜型PD-L1表达率为(78.7±3.1)%,HCC827细胞为(82.7±2.6)%。
- 厄洛替尼处理后PC9和HCC827细胞膜型PD-L1表达率分别为64.7%±3.1%和73.0%±2.6%,显著低于未处理组(P<0.05)。
- 厄洛替尼处理后PC9和HCC827细胞上清可溶性PD-L1水平分别为(0.680±0.120)ng/ml和(0.903±0.047)ng/ml,显著低于未处理组(P<0.01)。
- 在T细胞与EGFR突变肺癌细胞共培养体系中,厄洛替尼单药促进T淋巴细胞增殖(P<0.05),抗PD-L1单克隆抗体联合厄洛替尼作用更强(P<0.05)。
- 厄洛替尼处理前后IFN-γ分泌水平分别为(856.0±70.3)pg/ml和(1 697.3±161.0)pg/ml(P<0.001),膜型PD-L1表达率分别为(76.2±0.5)%和(50.9±0.9)%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on expression of soluble PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells. Methods: Flow cytometry was used to analyze the expression of membrane PD-LI. ELISA was performed to detect the level of sPD-L1 in the supernatant of cultured EGFR-mutated and wild type lung cancer cells before and after erlotinib treatment.After treated with anti-PD-L1 monoclonal antibody alone and in combination with erlotinib, the proliferation of T lymphocytes in co-culture system was measured using Cell Counting Kit-8 (CCK-8) assay. The expression levels of PD-LI and IFN-γ in tumor cells and T lymphocytes treated with erlotinib in co-culture system were analyzed by flow cytometry and ELISA, respectively. Results: PD-L1 was highly expressed in EGFR-mutated lung cancer PC9 cells (78.7±3.1)% and HCC827 cells (82.7±2.6)%.After treated with erlotinib, the expression rates of membrane PD-L1 in PC9 and HCC827 cells were down-regulated (64.7%±3.1% and 73.0%±2.6%, respectively), significantly lower than that in the two cell lines without erlotinib treatment (P<0.05), and the expression levels of sPD-L1 in the supernatant of PC9 and HCC827 cells were also down-regulated (0.680±0.120)ng/ml and (0.903±0.047)ng/ml, respectively, significantly lower than that in the two cell lines without erlotinib treatment (P<0.01). However, no significant changes of membrane PD-L1 and sPD-L1 expression were found in EGFR wild type lung cancer cells (H1299 and A549) before and after erlotinib treatment. In the co-culture system composed of T cells and EGFR-mutated lung cancer cells, treatment with erlotinib alone promoted the proliferation of T lymphocytes (P<0.05), and combined treatment of anti-PD-L1 monoclonal antibody with erlotinib had a stronger effect (P<0.05). In the co-culture system composed of T cells and EGFR wild type cell lines, the proliferation of T cells was not changed after using erlotinib alone or combination of erlotinib and anti-PD-L1 monoclonal antibody (P>0.05). Before and after treatment with erlotinib, the secretion levels of IFN-γ were (856.0±70.3)pg/ml and (1 697.3±161.0)pg/ml, respectively, showing a significant difference (P<0.001). The expression rates of membrane PD-L1 were (76.2±0.5)% and (50.9±0.9)%, respectively, also showing a significant difference (P<0.001). However, no significant changes in the expression of IFN-γ and membrane PD-L1 were found in the co-culture system composed of T cells and A549 cells. Conclusions: Anti-PD-L1 monoclonal antibody combined with EGFR-TKI can effectively promote the proliferation and secretion function of T lymphocytes in the microenvironment of EGFR-mutated lung cancer cells.
引用
- She Y, Pan X, Xing YF, et al. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27998463. doi:10.3760/cma.j.issn.0253-3766.2016.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。